Skip to content

A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence

A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032237
Enrollment
Unknown
Registered
2020-04-23
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Ezhou Hospital of traditional Chinese Medicine in Hubei Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Accorded with COVID-19's diagnostic criteria in convalescent stage; 2. The main clinical manifestations were fatigue, anorexia, abdominal distension, loose stool and other digestive symptoms, three of them appeared at the same time, or the (VAS) of single symptom visual analogue score was more than 4; 3. The patients who were discharged from hospital for more than 2 weeks were cured; 4. Aged 18-70 years old; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with oral drug difficulties due to basic diseases and other reasons; 2. accompanied by serious basic diseases affecting survival, including uncontrolled heart, lung, kidney, digestion, hematopathy, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, severe malnutrition, etc.; 3. allergic constitution, those who are allergic to the drugs involved in the treatment plan; 4. Pregnant or lactating women; 5. those who are unable to cooperate in mental state, suffer from mental illness, have no insight, and cannot express clearly; 6. those who are participating in other clinical trials; 7. According to the judgment of the researchers, there will be patients who affect the evaluation of efficacy and safety, such as complication or poor compliance.

Design outcomes

Primary

MeasureTime frame
Clinical symptoms include fatigue, poor appetite, abdominal distension, loose stool and so on.;

Contacts

Public ContactShao Xianzhi

Ezhou Hospital of traditional Chinese Medicine

372861095@qq.com+86 18071178279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026